STATUS: 14 QUESTIONS / SOURCE-LINKED
Questions about KLOW's legal standing
Information about the regulatory record. Not legal advice.
Is the KLOW blend legal?
There is no single 'legal/illegal' switch for a research peptide blend. The honest answer requires unpacking four separate frameworks. (1) FDA approval: no component of KLOW is FDA-approved for human therapeutic use [05][12]. (2) FDA compounding: as of September 29, 2023, BPC-157, KPV, injectable GHK-Cu, and the Thymosin Beta-4 fragment LKKTETQ are in Category 2 of the Interim 503A Bulks List, meaning licensed US compounding pharmacies cannot compound them for human use [05][12]. (3) DEA scheduling: none of the four components are scheduled controlled substances [12]. (4) Sport: BPC-157 is explicitly listed under WADA category S0, and the other three components are captured by the same category's catch-all language for non-approved substances [12]. 'Not a controlled substance' is not equivalent to 'legal for human use,' and 'legal to possess as research material' is not equivalent to 'legal to administer to a person.' This site does not give legal advice on any of these points.
Is KLOW FDA-approved?
No. No component of the KLOW blend is approved by the US Food and Drug Administration for any human therapeutic indication, and the blend itself has never been submitted for FDA review. GHK-Cu has the most extensive human topical safety data in cosmetic and dermatology contexts, but no approved drug product contains GHK-Cu as an active. BPC-157 has three published human reports in total — a Phase 1 healthy-volunteer safety study of PL 14736 and two small open-label pilots [07][08]. Full-length recombinant Thymosin Beta-4 (RGN-259) is in Phase 3 ophthalmic trials, but the TB-500 fragment sold as research material is not the same drug substance [14]. KPV has no published controlled human trial.
Is KLOW a controlled substance under the DEA?
As of 2026, none of GHK-Cu, BPC-157, TB-500, or KPV appear on the DEA Controlled Substances Act schedules [12]. This is a narrow factual statement and it does not by itself confer any other legal status. The FDA regulates approval and compounding under the Federal Food, Drug, and Cosmetic Act; the DEA regulates scheduled drugs under the CSA; state pharmacy boards regulate compounding practice within their jurisdictions; and WADA-signatory sport bodies regulate athlete use. A substance can be unscheduled by the DEA and still be a Category 2 ingredient that 503A pharmacies cannot compound.
Is KLOW WADA-prohibited?
Yes — every component is captured by the World Anti-Doping Agency Prohibited List. BPC-157 is explicitly listed under category S0 (Non-Approved Substances), prohibited at all times in and out of competition [12]. Category S0 covers 'any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use,' which catches GHK-Cu, the TB-500 fragment, and KPV by the same definition. The US Anti-Doping Agency (USADA) has issued public guidance specifically warning athletes about BPC-157, and the Department of Defense Operation Supplement Safety (OPSS) program has issued the same warning to service members [12].
Can a US compounding pharmacy legally prepare KLOW for a patient?
Under the FDA's Interim Policy on Compounding Using Bulk Drug Substances, a 503A pharmacy may compound only with bulk substances on Category 1 of the interim list (or with substances meeting the standards in section 503A(b) more broadly). Injectable GHK-Cu, BPC-157, KPV, and the Thymosin Beta-4 fragment LKKTETQ were placed in Category 2 on September 29, 2023, which under the interim policy means a 503A pharmacy may not compound them for human use [05][12]. The FDA has issued warning letters and the Department of Justice has prosecuted compounding pharmacies that distributed BPC-157 and related unapproved peptides; Tailor Made Compounding LLC entered a guilty plea involving forfeiture of approximately $1.79 million [12].
What does 'Research Use Only' on a KLOW vial actually mean?
'Research Use Only' (RUO) is a label indicating that a substance is intended for in vitro and animal laboratory research, and that it has not been manufactured to pharmaceutical standards. RUO material does not meet US Pharmacopeia (USP) standards for purity, identity, sterility, or endotoxin, and it is not lawful for human or veterinary compounding in the United States [12]. The RUO designation also does not authorize human administration — it is a labelling and quality-standards statement, not a permission. A vial marked RUO is not a pharmaceutical product and is not the same drug substance that would emerge from an FDA-approved manufacturing process.
Which of the four KLOW peptides did the FDA restrict in 2023?
All four were affected, though not identically. On September 29, 2023, BPC-157, KPV, injectable GHK-Cu, and the Thymosin Beta-4 fragment LKKTETQ were placed in Category 2 of the Interim 503A Bulks List, citing concerns about immunogenicity, peptide-related impurities, and limited human safety data [05][12]. Topical-route GHK-Cu remained on the Category 1 list, with restrictions, in the same update [12]. The 2023 PCAC briefing materials are the primary source for the agency's reasoning; the list is updated periodically and readers should consult the current FDA bulks-list publication for the present state.
Is KLOW legal to import or possess?
Import and possession rules are separate from compounding and prescribing rules, and they vary by jurisdiction. The DEA Controlled Substances Act does not currently schedule any of the four components [12]. FDA import regulations apply to unapproved drugs intended for human use; research material legitimately imported under an RUO label for laboratory research is treated differently from material intended for human administration. State and local regulations also apply. This site does not provide legal advice and does not advise on import or possession in any specific situation.
Are there any approved human medicines containing GHK-Cu, BPC-157, TB-500, or KPV?
No approved drug product in the United States contains any of these four peptides as an active pharmaceutical ingredient. GHK-Cu appears as an active in cosmetic formulations regulated under the FD&C Act's cosmetic provisions, not the drug provisions. Full-length recombinant Thymosin Beta-4 (RGN-259) is in Phase 3 ophthalmic trials for dry eye disease and neurotrophic keratopathy [14], but is not yet an approved product and is not chemically equivalent to the TB-500 fragment. BPC-157 was the subject of the Pliva PL 14736 program, which reportedly completed a Phase 2 ulcerative colitis trial but never published the results in a peer-reviewed clinical paper [12][16]. KPV has been the subject of multiple delivery-technology papers but no controlled human trial [09][11][12].
What happens to a pharmacy that sells KLOW for human use?
The Tailor Made Compounding LLC case is the most cited recent example. The Department of Justice prosecuted the compounding pharmacy in connection with distribution of BPC-157 and related unapproved peptides, and the company entered a guilty plea involving forfeiture of approximately $1.79 million [12]. The FDA has separately issued warning letters to multiple compounders. In late 2023, Evexias Medical Group and Farmakeio filed suit against the FDA challenging the procedural basis of the Category 2 placement; that litigation is ongoing as reported by Holt Law and trade press [12]. Outcomes vary by case and jurisdiction; readers should not extrapolate any specific enforcement action to predict how the agency or the courts will treat any other matter.
Is the KLOW blend itself characterized by any published clinical pharmacology?
No. The four-peptide blend has not been the subject of any published controlled trial, animal model, or pharmacokinetic characterization as a combination product. The 50 mg / 10 mg / 10 mg / 10 mg ratio that appears on commercial vials is a vendor convention, not a tested formulation [08]. Each component has its own literature; the combination does not. Safety, stability, and peptide-peptide interaction data for the four together are vendor-claimed rather than peer-reviewed.
What is the difference between full-length Thymosin Beta-4 and the TB-500 fragment?
Thymosin Beta-4 is a 43-amino-acid protein that functions as the principal G-actin sequestering peptide in mammalian cells [13]. RGN-259 is full-length recombinant Tβ4 and is in Phase 3 ophthalmic trials [14]. TB-500 is a synthetic 17-residue fragment marketed as corresponding to the actin-binding region. The fragment is not the same drug substance as the full-length molecule, and clinical data on RGN-259 — including its safety profile in ophthalmic use — does not transfer directly to the fragment. Buyers and readers conflate the two more often than the literature does.
Did the Pliva BPC-157 ulcerative colitis trial show that BPC-157 works in humans?
The Pliva PL 14736 Phase 2 ulcerative colitis trial reportedly completed but the data was never published in a peer-reviewed clinical paper [12][16]. Without published methods, results, and adverse-event reporting, the trial cannot be cited as evidence of efficacy or safety. The 2025 HSS Journal systematic review noted that only one human BPC-157 study (the 2024 interstitial cystitis open-label pilot in 12 women) appears in the indexed literature [07][08]. A 2025 Cureus narrative review reached the same conclusion and explicitly called for randomized controlled trials [18].
Is the regulatory status of KLOW the same outside the United States?
Regulatory status varies by jurisdiction. The European Medicines Agency has not approved any of the four components for human therapeutic use [12]. Health Canada has not approved them [12]. The WADA Prohibited List applies globally to athletes in WADA-signatory sports, so the S0 status of BPC-156 and the catch-all coverage of the other three components do not depend on national approval [12]. Readers outside the United States should consult their own national medicines regulator and anti-doping authority for the current local position.